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Abstract
Background:  For decades, there is an unresolved debate about adequate prescription of
antibiotics for patients suffering from exacerbations of chronic obstructive pulmonary disease
(COPD). The aim of this systematic review was to analyse randomised controlled trials
investigating the clinical benefit of antibiotics for COPD exacerbations.
Methods: We conducted a systematic review of randomised, placebo-controlled trials assessing
the effects of antibiotics on clinically relevant outcomes in patients with an exacerbation. We
searched bibliographic databases, scrutinized reference lists and conference proceedings and asked
the pharmaceutical industry for unpublished data. We used fixed-effects models to pool results.
The primary outcome was treatment failure of COPD exacerbation treatment.
Results: We included 13 trials (1557 patients) of moderate to good quality. For the effects of
antibiotics on treatment failure there was much heterogeneity across all trials (I2 = 82%). Meta-
regression revealed severity of exacerbation as significant explanation for this heterogeneity (p =
0.016): Antibiotics did not reduce treatment failures in outpatients with mild to moderate
exacerbations (pooled odds ratio 1.09, 95% CI 0.75–1.59, I2 = 18%). Inpatients with severe
exacerbations had a substantial benefit on treatment failure rates (pooled odds ratio of 0.25, 95%
CI 0.16–0.39, I2 = 0%; number-needed to treat of 4, 95% CI 3–5) and on mortality (pooled odds
ratio of 0.20, 95% CI 0.06–0.62, I2 = 0%; number-needed to treat of 14, 95% CI 12–30).
Conclusion: Antibiotics effectively reduce treatment failure and mortality rates in COPD patients
with severe exacerbations. For patients with mild to moderate exacerbations, antibiotics may not
be generally indicated and further research is needed to guide antibiotic prescription in these
patients.
Background
The use of antibiotics in exacerbations of chronic obstruc-
tive pulmonary disease (COPD) remains controversial
[1,2]. It is unclear which patients should receive antibiot-
ics. The uncertainty arises from a complex clinical situa-
tion where the cause of the exacerbation is often
unidentifiable [3]. Around 40–50% of exacerbations may
be attributed to bacteria while other causes include viral
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infections or environmental irritants [4-6]. Even if bacte-
ria are identified, it is uncertain whether they actually
caused the exacerbation or whether they were present as
part of the flora before the exacerbation.
Diagnostic tests cannot reliably distinguish between bac-
terial, viral or other origins of exacerbations. As a conse-
quence, many physicians decide to be on the "safe" side
and prescribe antibiotics[7]. The uncertain role of antibi-
otics is reflected by current guidelines that insufficiently
inform physicians about adequate prescription of antibi-
otics [3,8]. Guidelines suggest adding an antibiotic if spu-
tum is purulent, if sputum volume is increased and/or if
fever is present. However, evidence supporting this sug-
gestion is not based on randomised trials. There are no
randomised trials where prescription of antibiotics was
guided by purulence of sputum or other criteria. In addi-
tion, the extent of symptom worsening is difficult to
standardise and utility of sputum assessment is controver-
sial [9,10].
A systematic review of randomised, placebo-controlled
trials could inform the debate about the role of antibiotics
substantially. Eleven years ago, a meta-analysis suggested
a small improvement of lung function by antibiotics in
COPD patients with an exacerbation, but the review was
limited by the restriction to articles in English and its
focus on lung function [11]. A recent systematic review
[12] considered patient-important outcomes but missed
some studies and included a non-randomised trial[13].
Inclusion of all available trials is, however, crucial to
avoid selection bias and to study factors modifying the
effects of antibiotics such as severity of exacerbation.
Therefore, our aim was to review all randomised placebo-
controlled trials that assessed the effects of antibiotics on
patient-important outcomes in COPD patients suffering
from exacerbations.
Methods
Selection criteria
We included randomised controlled trials comparing any
antibiotics with placebo or no antibiotics in COPD
patients suffering from an acute exacerbation defined as a
worsening of a previous stable situation with symptoms
such as increased dyspnea, increased cough, increased
sputum volume or change in sputum colour. We consid-
ered studies if >90% of patients had a clinical (physician-
based) diagnosis of COPD or, ideally, spirometrically
confirmed COPD. We excluded studies of patients with
acute bronchitis, pneumonia, asthma or bronchiectasis.
We included trials evaluating any antibiotics that were
administered orally or parenterally daily for a minimum
period of at least three days. We chose three days because
this is the minimum duration for which antibiotics are
usually prescribed in clinical practice for COPD exacerba-
tions.
The outcome measure of primary interest was treatment
failure defined as (1) no resolution of symptoms and
signs as reported by patients or physicians or as (2) need
for further antibiotics. Outcome measures of secondary
interest were duration of hospital admission, admission
to an intensive care unit, health-related quality of life,
symptoms, mortality, and any adverse events registered
during the study period.
Search strategy
The search was carried out by information specialists
(Bazian, London, UK) and included searches in the
Cochrane Central Register of Controlled Trials (CEN-
TRAL, 2005 issue 4), PREMEDLINE (1960 to 1965),
MEDLINE (1966 to March 2006), EMBASE (1974 to
March 2006), the Database of Abstracts of Reviews of
Effectiveness (DARE, March 2006). We entered all
included studies into the Pub-med "related articles" func-
tion and the science citation index. In addition, we scruti-
nised the reference lists of included studies and review
articles as well the conference proceedings of the interna-
tional congresses of the American Thoracic Society and
the European Respiratory Society from 2000 to 2006 since
these studies might not have been fully published yet. We
also contacted representatives of the pharmaceutical
industry for additional published or unpublished data
(Novartis, GlaxoSmithKline, AstraZeneca, Boehringer-
Ingelheim, Pfizer and MSD). Finally, we searched interna-
tional data bases for trial registration to identify ongoing
or recently completed trials [14-16].
Study selection
Two members of the review team independently assessed
the titles and abstracts of all identified citations without
imposing any language restrictions. The reviewers then
evaluated the full text of articles that seemed potentially
eligible by one of the reviewers. Final decisions on in- and
exclusion were recorded in the Endnote file and agree-
ment was assessed using chance-adjusted kappa statistics.
Data extraction
One reviewer recorded details about study design, inter-
ventions, patients, outcome measures and results in pre-
defined Windows Excel forms and a second reviewer
checked data extraction for correctness. We used a small
sample of studies with high likelihood for inclusion to
pilot test the data form. To obtain missing information,
we tried to contact authors of primary studies at least three
times by telephone or email.
We entered dichotomous data on into 2 × 2 tables. For
continuous outcomes, we recorded summary estimatesRespiratory Research 2007, 8:30 http://respiratory-research.com/content/8/1/30
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per group (means, medians) with measures of variability
(SD) or precision (SEM, CI). In trials with two groups
receiving different antibiotics, we treated these groups as
one group if the effects of the two antibiotics did not differ
statistically significantly or clinically importantly.
Quality assessment
Two reviewers independently evaluated the quality of
included trials using a list of selected quality items assess-
ing components of internal validity [17]. We recorded the
initial degree of discordance between the reviewers and
corrected discordant scores based on obvious errors. We
resolved discordant scores based on real differences in
interpretation through consensus or third party arbitra-
tion.
Statistical analysis
We expressed treatment effects as odds ratios with corre-
sponding 95% confidence intervals (CI) and calculated,
based on pooled odds ratios, numbers-needed-to-treat.
We pooled data across studies only in absence of signifi-
cant heterogeneity (p > 0.1 for χ2) using fixed effects mod-
els (inverse variance method). We analysed comparisons
with events only in one group by adding 0·5 to "zero-
cells".
We assessed heterogeneity using χ2 statistic and expressed
the proportion of variation due to heterogeneity as I2 [18].
We explored sources of heterogeneity using meta-regres-
sion following a priori defined explanations, which
included severity of exacerbation (defined as severe if
requiring inpatient treatment and as mild to moderate
requiring outpatient treatment according to the Opera-
tional Classification of Severity of the European Respira-
tory and American Thoracic Societies [19]), generation of
antibiotics (before and after 1980), definition of out-
comes, length of follow-up (≤ and > 10 days) and study
quality. We assessed publication bias using the regression-
based test of Egger [20].
We conducted all analyses with STATA for windows ver-
sion 8.2, Stata Corp; College Station, TX)
Results
Identification of studies
Figure 1 summarises the process of identifying eligible
clinical trials. We identified 765 citations from electronic
databases and selected 35 of them for full text assessment.
Together with 30 additional citations from hand-search-
ing we studied 65 publications in detail. We included 13
trials with 1557 COPD patients in the analyses. We
excluded most trials because they compared different anti-
biotics without having a placebo control group. From trial
registers, we identified four randomised trials that are still
ongoing [21-24]. The pharmaceutical industry did not
provide any unpublished data.
Study characteristics
Table 1 shows the characteristics of the trials that were
published between 1957 and 2001. In seven trials,
patients suffered from mild to moderate exacerbations
receiving outpatient treatment [25-31]. Six trials included
patients admitted to the hospital because of severe exacer-
bations [32-37]. Nouira [34] included patients with very
severe exacerbations, who needed mechanical ventilation.
Severity of underlying COPD could not be compared
across trials because lung function and other parameters
were reported inconsistently between 1957 and 2001. In
all trials, patients received co-interventions such as sys-
temic corticosteroids, theophylline, β-mimetics, gastric
ulcer prophylaxis or ventilation support with or without
oxygen. But the proportion of patients receiving co-inter-
ventions was rarely specified and could not be considered
as potential confounders in the analyses.
Ten trials used treatment failure as an outcome although
definitions varied from patient reported failure of symp-
tom resolution to the physicians' decision to prescribe
additional treatment [25-28,30-32,34,36,37]. Four trials
including patients with severe exacerbations assessed
mortality [34-37] and three trials [32-34] the duration of
hospital stay.
In one trial, analyses were based on the number of 116
patients with exacerbations as well as on the total number
of exacerbations (n = 362) [26]. In our meta-analyses, we
considered the analysis based on the number of patients
only because the other trials also followed this approach.
In addition, Anthonisen et al used a cross-over design for
patients with more than one exacerbation. Thereby,
patients with more than one exacerbation counted in the
antibiotic and placebo group. In addition assessing anti-
biotics with a cross-over design may not fulfil the impor-
tant requirement for cross-over studies that patients must
return to their baseline state before starting the cross-over.
COPD patients often do not fully recover from exacerba-
tions and are, therefore, unlikely to return to their base-
line state.
The quality of the trials was moderate to good (table 2).
Ten trials described their method of randomisation. Con-
cealment of random allocation was reported in eight trials
and in nine trials, outcome assessors were blinded. Initial
agreement for quality assessment among the two review-
ers was high (88% for all items, chance-corrected kappa =
0.75, p < 0.001).Respiratory Research 2007, 8:30 http://respiratory-research.com/content/8/1/30
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Effects of antibiotics
Median treatment failure rate was 0.12 for the antibiotic
groups (range 0.00 to 0.47) and 0.34 for the placebo
groups (range 0.10 to 0.80). Thus across all trials, one out
of eight patients with antibiotics had a treatment failure
whereas one out of three patients had a treatment failure
with placebo.
Figure 2 shows that the effects of antibiotics were very het-
erogeneous across trials (I2 = 82%). When we explored
predefined sources of heterogeneity in meta-regression
analyses we found that generation of antibiotic (p = 0.55),
definition of outcomes (p = 0.20), length of follow-up (p
= 0.38) and study quality (p = 0.92) did not explain het-
erogeneity. We could not assess severity of COPD as a
source of heterogeneity because lung function parameters
were not reported in earlier trials.
Across nine of ten trials effects of antibiotics were substan-
tially larger in patients with severe exacerbations. One
trial in patients with mild to moderate exacerbations
totally contradicted this trend with an unexpectedly large
effect (OR 0.16, 95% 0.09–0.27) [25]. But this trial dif-
fered substantially from other trials including patients
with mild to moderate exacerbations. It had a short fol-
low-up of 5 days and a treatment failure rate of 0.50 in
control patients (median follow-up of 17 days and
median treatment failure rate of 0.19). After five days,
adjustment of exacerbation treatment is important but
seems too early to determine whether treatment was suc-
cessful or not. Exacerbations last longer than five days so
that effectiveness of interventions should be evaluated
later on as it was the case in the other trials [38]. It must
be stated that this trial actually had a follow-up assess-
ment after 14 days but these data were not provided in the
publication. In a personal communication, one of the
authors told us that treatment effects were smaller at that
14 days follow-up but he was unable to provide the data
because they are stored by the pharmaceutical company
funding the trial [39].
Study flow from identification to final inclusion of studies Figure 1
Study flow from identification to final inclusion of studies.
Total citations identified from electronic databases
n = 765
Excluded after full text assessment
Reasons for exclusion:
- No placebo-control group n= 38
- No RCT n= 7
- Ongoing RCT n = 4
- No clinical outcome n= 2
- No COPD exacerbation n = 1
n = 52 Studies included in review
- From electronic databases n= 9
- From hand searching n= 4
n = 13
Citation excluded after screening titles 
and abstracts
n = 730
Studies retrieved for detailed evaluation:
- From electronic databases: n= 35
- From hand searching (reference lists of reviews 
and studies, “related articles” function of 
PubMed and trial registers): n= 30
n = 65
Agreement: 97%
Kappa = 0.90, p<0.001Respiratory Research 2007, 8:30 http://respiratory-research.com/content/8/1/30
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When we did the meta-analysis without this trial, we
found that severity of exacerbations was associated signif-
icantly with treatment effects (p = 0.016). Figure 3 shows
the pooled results separately for trials including patients
with mild to moderate exacerbations and patients with
severe exacerbations. For mild to moderate exacerbations,
antibiotics did not significantly reduce the risk for treat-
ment failure (OR 1.09, 95% CI 0.75–1.59, I2 = 18%).
When the Allegra trial [25] was included in the meta-anal-
ysis the pooled estimate favoured antibiotics (OR 0.55,
95% CI 0.41–0.74, with a number-needed to treat of 9,
95% CI 6–16) but there was a large amount of heteroge-
neity (I2 = 87%). Antibiotics had a large effect in severe
exacerbations (OR 0.25, 95% CI 0.16–0.39, I2 = 0%) with
a number-needed to treat of 4 (95% CI 3–5).
Effect modification by severity of exacerbation was con-
firmed by subgroup analyses of the trial that also pre-
sented comparisons based on exacerbations as described
above [26]. There was no statistically significant effect on
treatment failure rates in mild exacerbations (Anthonisen
type 2 and 3 corresponding to the presence of one or two
aggravated symptoms including more severe dyspnea,
increased sputum volume and sputum purulence [26],
Table 1: Characteristics of included trials
Study Population Interventions Outcomes and length of follow-up
Elmes 1957 [28] 88 COPD patients (84% males, mean age 54 years). 
Patients were instructed to take antibiotic/placebo 
without a doctor visit as soon as new or aggravated 
respiratory symptoms were present.
Severity of exacerbation: Mild to moderate
Group 1: Oxytetracycline 1 g/day per os 
for 5–7 days
Group 2: Placebo for 5–7 days
Treatment success/failure (need for 
further antibiotics), time off work, 
number of days with symptoms
Mean follow-up: 17 days
Berry 1960 [27] 58 COPD patients (53% males, mean age 59 years) 
with general practitioner visit for new or aggravated 
respiratory symptoms. Patients with severe 
exacerbations were not included because antibiotics 
were deemed indispensable.
Severity of exacerbation: Mild to moderate
Group 1: Oxytetracycline 1 g/day per os 
for 5 days
Group 2: Placebo for 5 days
Treatment success/failure (patient 
reported)
Mean follow-up: 14 days
Fear 1962 [29] 62 COPD patients (% males and mean age not stated) 
with outpatient visit to Bronchitis and Asthma Clinic 
for new or aggravated respiratory symptoms.
Severity of exacerbation: Mild to moderate
Group 1: Oxytetracycline 1 g/day per os 
for 7 days
Group 2: Placebo for 7 days
Improvement of symptoms, days of 
illness
Mean follow-up: 14 days
Petersen 1967 [35] 19 COPD patients (53 % males, mean age 62 years) 
with hospital admission for exacerbation.
Severity of exacerbation: Severe
Group 1: Chloramphenicol 2 g/day 
(route of administration unclear) for 10 
days
Group 2: Placebo for 10 days
Mortality, patient-reported well-being
Mean follow-up: 10 days
Pines 1968 [37] 30 COPD patients (% males not stated, mean age 68 
years) with hospital admission for exacerbation.
Severity of exacerbation: Severe
Groups 1: Penicillin 6 million units and 
streptomycin 1 g/day parenterally for 14 
days
Group 2: Placebo for 14 days
Treatment success/failure (physician 
reported), mortality
Mean follow-up: 14 days
Pines 1972 [36] 259 COPD patients (100% males, mean age 71 years) 
with hospital admission for exacerbation. Patients with 
very severe exacerbation were not included because 
antibiotics were deemed indispensable.
Severity of exacerbation: Severe
Groups 1 and 2: Tetracycline 2 g or 
chloramphenicol 2 g/day per os for 12 
days
Group 3: Placebo for 12 days
Treatment success/failure (physician 
reported), mortality, incidence of 
relapses
Mean follow-up: 12 days
Anthonisen 1987 [26] 116 COPD patients (80% males, mean age 67 years). 
Initially, 173 patients were included for observation. 
Of these, 116 reported worsening of respiratory 
symptom and received randomly assigned antibiotics 
or placebo on an outpatient base. 57 patients did not 
experience an exacerbation.
Severity of exacerbation: Mild to moderate
Group 1: Trimethoprim-
sulfamethoxazol 1.9 g or amoxicillin 1 g 
or doxycycline 0.1–0.2 g/day per os for 
10 days
Group 2: Placebo for 10 days
Treatment success/failure (patient 
reported symptoms)
Follow-up: 21 days
Manresa 1987 [33] 19 COPD patients (% males not stated, mean age 67) 
with hospital admission for exacerbation.
Severity of exacerbation: Severe
Group 1: Cefaclor 1.5 g/day per os for 8 
days
Group 2: Placebo for 8 days
Duration of hospitalisation
Mean follow-up: 13 days
Allegra 1991 [25] 335 COPD patients (73% males, mean age 63 years). 
Patients received antibiotic/placebo on an outpatient 
base in case of self-reported worsening of respiratory 
symptoms.
Severity of exacerbation: Mild to moderate
Group 1: Amoxicillin-clavulanic acid 2 g/
day per os for 5 days
Group 2: Placebo for 5 days
Treatment success/failure (patient 
reported symptoms and clinical signs)
Mean follow-up: 5 days
Alonso Martinez 1992 [32] 90 COPD patients (84% males, mean age 68 years) 
with hospital admission for exacerbation.
Severity of exacerbation: Severe
Groups 1 and 2: : Trimethoprim-
sulfamethoxazol 1.9 g or amoxicillin-
clavulanic acid 1.9 g/day per os for 8 days
Group 3: Placebo for 8 days
Treatment success (need for further 
antibiotics), duration of hospitalisation
Mean follow-up: 8 days
Jorgensen 1992 [30] 270 COPD patients (43% males, mean age 60 years) 
with general practitioner visit for new or aggravated 
respiratory symptoms.
Severity of exacerbation: Mild to moderate
Group 1: Amoxicillin 1.5 g/day per os 
for 7 days
Group 2: Placebo for 7 days
Treatment success/failure (patient 
reported symptoms)
Mean follow-up: 8 days
Sachs 1995 [31] 61 COPD patients (% males not stated, mean age not 
stated) with general practitioner visit for new or 
aggravated respiratory symptoms.
Severity of exacerbation: Mild to moderate
Groups 1 and 2: Amoxicillin 1.5 g or 
co-trimoxazol 1.9 g/day per os for 7 days
Group 3: Placebo for 7 days
Treatment success/failure (patient 
reported symptoms)
Mean follow-up: 35 days
Nouira 2001 [34] 93 COPD patients (90% males, mean age 66 years) 
with admission to intensive care unit for exacerbation 
and need for mechanical ventilation.
Severity of exacerbation: Severe
Group 1: Ofloxacin 0.4 g/day per os for 
10 days
Group 2: Placebo for 10 days
Treatment success (need for further 
antibiotics), mortality, duration of 
hospitalisation
Mean follow-up: 10 daysRespiratory Research 2007, 8:30 http://respiratory-research.com/content/8/1/30
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OR 0.63, 95% CI 0.25–1.60) whereas in more severe exac-
erbations (Anthonisen type 1, presence of all three symp-
toms) the effect reached statistical significance (OR 0.37,
95% CI 0.16–0.85) with a number-needed to treat of 5
(95% CI 3–25).
Effects of antibiotics on mortality confirmed the benefi-
cial effect for patients with severe exacerbations (Figure 4).
Antibiotics reduced mortality substantially (OR 0.20,
95% CI 0.06–0.62, I2 = 0%) and the number needed to
treat to prevent one death was 14 (95% CI 12–30).
Duration of hospital admission was not reduced in two
trials (difference between groups 0.5 days, 95% CI -3.1–
4.1 [33] and -0.3 days, 95% CI -1.3–0.7[32]) whereas in
patients with very severe exacerbations requiring mechan-
ical ventilation, hospital admission could be shortened by
9.6 days (95% CI 6.4–12.8) [34].
Adverse effects
Median rate for adverse effects (mostly mild gastrointesti-
nal complaints) was 0.15 (range 0.05–0.60) for the anti-
biotic and 0.08 (range 0.04–0.13) for the placebo groups
(figure 5). In two studies, adverse effects occurred signifi-
cantly more often in the placebo groups. We did not pool
the results statistically because there was significant heter-
ogeneity (I2 = 62%).
Publication bias
The Egger test of heterogeneity (regression coefficient -
0.11, 95% CI -2.37–2.15, p = 0.91) did not reveal any
publication bias.
Discussion
Principal findings
This systematic review shows that the effects of antibiotics
are likely to depend on the severity of COPD exacerba-
tions. The meta-analyses indicate that COPD patients
with mild to moderate exacerbations may not benefit
from antibiotics as part of the exacerbation treatment. In
contrast, trials including patients with severe exacerba-
tions showed that antibiotics led to a substantial reduc-
tion in treatment failure and mortality rates.
Strengths and weaknesses
Strengths of this study include adherence to rigorous sys-
tematic review methodology, the comprehensive litera-
ture search and contacts to authors who provided
additional information [25,31]. Furthermore, we carefully
addressed heterogeneity of study results using predefined,
clinically plausible sources of heterogeneity in formal
meta-regression analysis.
Although treatment failure is commonly used in meta-
analyses [12,40], it is a limitation that definitions of treat-
ment failure often differ across trials. It is difficult to
standardise the definition of treatment failure because it
may include patient reported symptoms, clinical signs
and results from laboratory tests or imaging. We do not,
however, have reason to believe that different definitions
of treatment failure caused heterogeneity in our meta-
analyses. Another limitation is that severity of underlying
COPD could not be studied as potential source of hetero-
geneity. The definitions and classifications of COPD
changed over the years so that no uniform classifications
of COPD such as the GOLD stages could be extracted from
the studies. Also, we could not assess the influence of
other factors such as season, co-morbidities or co-medica-
tions such as systemic steroids or bronchodilators as they
were reported poorly and inconsistently. Finally, the
included trials did not study patient-important outcomes
such as health-related quality of life, which is heavily
influenced by exacerbations [41] and one of the main tar-
gets of COPD treatments [19].
Meaning of the study
We quantified the influence of severity of exacerbations
on the effects of antibiotics using the Operational Classi-
Table 2: Quality assessment
Description of 
randomisation 
procedure
Pre- 
stratification
Concealment 
of random 
allocation
Description 
of loss to 
follow-up
Blinding of 
patients
Blinding of 
treatment 
providers
Description 
of co- 
interventions
Blinding of 
outcome 
assessors
Intention-to-
treat-analysis
Adjustment 
for 
imbalances
Elmes 1957 [28] 1 0 1 1 1 1 1 1 1 0
Berry 1960 [27] 1 0 1 0 1 1 1 1 1 0
Fear 1962 [29] 1 0 1 1 1 1 0 1 1 0
Petersen 1967 [35] 1 1 0 1 1 0 0 0 0 1
Pines 1968 [37] 1 0 1 1 1 1 0 1 1 0
Pines 1972 [36] 1 0 1 1 1 1 1 1 1 0
Anthonisen 1987 [26] 1 0 0 1 1 1 1 1 1 0
Allegra 1991 [25] 0 0 0 1 1 1 1 1 0 0
Alonso Martinez 1992 [32] 1 0 1 1 1 1 1 0 1 0
Jorgensen 1992 [30] 0 0 0 1 1 1 1 1 1 1
Sachs 1995 [31] 1 0 1 1 1 1 1 0 1 0
Nouira 2001 [34] 1 0 1 1 1 1 1 1 1 0
0 = not addressed; 1 = partially or fully addressedRespiratory Research 2007, 8:30 http://respiratory-research.com/content/8/1/30
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fication of Severity of the European Respiratory and Amer-
ican Thoracic Society [19]. The major advantage of this
classification over earlier ones [26] is that it is simple to
apply. But one needs to consider that severity of exacerba-
tions is not the only determinant for hospital admission
and that co-morbidity and social circumstances also play
an important role. As long as the mechanisms of exacerba-
tions are not fully understood and cannot be assessed in
detail by pathophysiological variables, the Operational
Classification of Severity may describe exacerbations most
comprehensively. This simplification comes at the price of
not discriminating between different forms of exacerba-
tions that can be treated on an outpatient base. It is, how-
ever, unclear, whether this distinction is necessary in
general. Even if there is an effect of antibiotics in more
severe exacerbations of outpatients it is likely to be small.
The four ongoing trials, that all include outpatients, may
inform us in this regard [21-24].
The results of our systematic review may have important
implications for clinical practice and help to inform dis-
cussions that are ongoing for decades. Most patients with
COPD exacerbations who do not need hospital admission
may not benefit from immediate antibiotic treatment. The
most prudent choice for these patients might be to with-
hold antibiotics at first while first line management
should include bronchodilators, systemic corticosteroids,
patient instruction to use medications correctly as well as
follow-up visits [3,19]. If patients do not recover or show
further worsening of health status, antibiotics might still
be considered after 3 to 5 days of first line treatment.
Thereby, a substantial amount of antibiotics could be
spared with positive consequences for the patient and
society (adverse effects, antibiotic resistance and costs.)
Unanswered questions and future research
To base this proposed strategy on solid grounds, a ran-
domised, non-inferiority trial comparing the clinical
effectiveness and amount of antibiotics used with imme-
diate antibiotic treatment and a watchful-waiting strategy
would be highly welcome. Thereby, investigators could
show whether a watchful-waiting strategy is clinically not
disadvantageous but associated with reduced use of anti-
biotics.
Factors other than treatment setting that may guide anti-
biotic treatment also deserve further research. For exam-
ple, studies showed promising results for procalcitonin
guidance of antibiotic treatment in lower respiratory tract
infections and might be evaluated for COPD exacerba-
Forest plot showing ten studies that compared the effects of antibiotics and placebo on treatment failure Figure 2
Forest plot showing ten studies that compared the effects of antibiotics and placebo on treatment failure. The x-axis repre-
sents the odds ratio for treatment failure. An odds ratio below 1 represents a lower chance of treatment failure with antibiot-
ics. Studies not reporting treatment failures could not be included in the meta-analysis.
Favours 
antibiotics
Favours 
placebo
Test for heterogeneity χ2=50.53, I2=82%, p<0.001
Odds ratio (95% CI)
0.01 0.1 1 10
Study Odds ratio (95% CI) Treatment failures
(No of Events/Total No)
Antibiotics Placebo
0.97 (0.23-4.18) Elmes 1957 4/42 4/41
0.08 (0.00-1.47) Berry 1960 0/26 5/27
0.13 (0.02-0.66) Pines 1968 5/15 12/15
0.31 (0.18-0.52) Pines 1972 58/176 53/86
1.81 (0.85-3.83) Anthonisen 1987 28/59 19/57
0.16 (0.09-0.27) Allegra 1991 24/176 79/159
0.27 (0.07-1.04) Alonso Martinez 1992 4/61 6/29
1.05 (0.64-1.72) Jorgensen 1992 49/132 49/136
1.06 (0.18-6.30) Sachs 1995 4/40 2/21
0.13 (0.03-0.48) Nouira 2001 3/47 16/46Respiratory Research 2007, 8:30 http://respiratory-research.com/content/8/1/30
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tions as well [42, 43]. Also, a recent study showed that
patient-reported sputum purulence was an excellent pre-
dictor of positive bacteria cultures [44]. Although the
study was too small for multivariable analyses and no
patient-important outcomes were assessed, the usefulness
of sputum purulence to guide antibiotic treatment should
be further studied.
Finally, future studies should explore the long-term effects
of antibiotics when given for acute exacerbations. The tri-
als included in this review only assessed the effects on
short-term outcomes such as treatment failure or mortal-
ity. However, it may be possible that antibiotics eradicate
bacteria that could cause exacerbations in the future. Thus
antibiotics might prolong the exacerbation-free interval or
even reduce the number of exacerbations.
Conclusion
Our systematic review informs the debate about appropri-
ate prescription of antibiotics for COPD exacerbations. As
long as exacerbations remain an ill-defined event, the dis-
tinction between in- and outpatient treatment may serve
as simple guidance to decide for or against antibiotics.
Patients with severe exacerbations requiring hospital
admission benefit substantially from antibiotics. In out-
patients with mild to moderate exacerbations, antibiotics
appear to offer no benefits in general. Further research will
show how the subgroup of patients with mild to moderate
exacerbations, who might benefit from antibiotics, can be
identified.
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